8-K
false000110935400011093542025-05-142025-05-14

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 14, 2025

 

BRUKER CORPORATION

(Exact name of registrant as specified in its charter)

 

 

 

 

 

Delaware

000-30833

04-3110160

(State or other jurisdiction of

(Commission

(I.R.S. Employer

incorporation)

File number)

Identification No.)

 

40 Manning Road

Billerica, MA 01821

(Address of principal executive offices) (Zip Code)

 

(978) 663-3660

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class

Trading Symbol(s)

Name of Each Exchange on Which Registered

Common Stock, $0.01 par value per share

BRKR

The Nasdaq Global Select Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 


 

Section 8 - Other Events

Item 8.01. Other Events

 

On May 14, 2025, Bruker Corporation (the “Company”) issued a press release regarding a settlement reached with 10x Genomix, Inc. on a previously disclosed litigation matter. A copy of the press release is attached hereto as Exhibit 99.1.

 

 

 

Section 9 – Financial Statements and Exhibits

 

Item 9.01. Financial Statements and Exhibits.

 

(d)

Exhibits.

Number

Description

99.1

Press release issued by Bruker Corporation dated May 14, 2025.

 

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document).


 

 

 

 


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BRUKER CORPORATION
(Registrant)

 Date: May 14, 2025

By:

/s/ GERALD N. HERMAN

Gerald N. Herman

Executive Vice President and Chief Financial Officer

 

 

 


img53376846_0.jpg

Bruker and 10x Genomics Reach Global Settlement of Patent Litigation

BILLERICA, Massachusetts – May 14, 2025Bruker Corporation (Nasdaq: BRKR) today announced that Bruker and 10x Genomics have reached a final settlement to resolve their patent disputes and dismiss multiple litigations, with global patent cross license agreements between the two companies. In connection with the settlement, all ongoing lawsuits and administrative proceedings filed by both companies in several countries, including actions pending in the United States, in Germany, and before the European Unified Patent Court, will be withdrawn.

“We’re pleased that we have reached a worldwide settlement with 10x, putting an end to all litigation between us,” said Mark R. Munch, Ph.D., President of the Bruker Nano Group. “This is a great outcome for the scientific community, who can continue their work using Bruker’s CosMx® and GeoMx® spatial biology platforms without concern that litigation could interfere with their advancements in oncology, neurobiology, and other fields of research. We’re excited to be able to focus on the impact and value that these products provide for discovery research, translational research and precision medicine and we’re happy to have the distraction and expense of these legal cases behind us.”

 

About Bruker Corporation – Leader of the Post-Genomic Era

 

Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit www.bruker.com.

 

Investors:
Joe Kostka
Director, Investor Relations
Bruker Corporation
T: +1-978-313-5800
E: [email protected]

 

Media:
Johnny Lyssand
Director, Downstream Marketing
Bruker Spatial Biology

T: +1 (206) 790-2843

E: [email protected]